Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas. In a single-cen...

Full description

Bibliographic Details
Main Authors: Yaqing Cao, Wenyi Lu, Rui Sun, Xin Jin, Lin Cheng, Xiaoyuan He, Luqiao Wang, Ting Yuan, Cuicui Lyu, Mingfeng Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
B-cell non-Hodgkin lymphoma (B-NHL)
anti-CD19 chimeric antigen receptor T cells
immune check point blocade
combination
safe and effective
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00767/full

Similar Items

Similar Items